Site icon Asrar Qureshi’s Blogs

Pakistan Pharma Industry SWOT – Part 16 – Asrar Qureshi’s Blog Post #607

Dear Colleagues!  This is Asrar Qureshi’s Blog Post #607 for Pharma Veterans. Pharma Veterans welcome sharing of knowledge and wisdom by Veterans for the benefit of Community at large. Pharma Veterans Blog is published by Asrar Qureshi onWordPress, the top blog site. Please email to asrar@asrarqureshi.com for publishing your contributions here.

Opening Note

February 2022 marks my completing 47 years of working in Pharma Industry. Allah be praised. I am still working. The first half of my working career was spent in Multinational companies, and the latter half in the Local Pharma, making me well-versed with both innovators and generics markets. I also had the opportunity to work in business as well as operations.

My journey of near half century is also the journey of Pharma Industry in Pakistan. Great changes have occurred in this time and a lot could be written about it. In my blogs, which were started about four and a half years ago, I have covered several topics related to Pakistan Pharma Industry. This multi-part series shall do and review the SWOT – Strengths, Weaknesses, Opportunities, Threats – of the Pharma Industry.

SWOT – OPPORTUNITIES……

As mentioned in the introduction of SWOT, Strengths and Weaknesses are internal while Opportunities and Threats are external.

Another point to mention is that my focus is mostly on Local Pharma which is dominating the Pharma Industry since many years.

  1. Acceptance of Generic Products by Doctors and Patients – The change took time, but it did happen finally. Doctors mattered more because whatever they prescribed would be accepted by the patients. In the beginning, the doctors were unsure about the efficacy of generic drugs; safety wss no one’s concern. They were reluctant to switch and did so only if they wanted to give economic relief to certain patients who were not able to afford the innovator drugs. They rationalized prescribing of generic drugs on this basis, and many considered it appropriate to inform the patient also. I remember taking a patient to a leading gastroenterologist in Lahore, who did not know me personally. The consultant wrote the prescription and then explained to me. “This here is the original drug, but it is expensive. Below is its cheaper version. The price may be 20-25% less, and efficacy may be 40-50% less”. This sentiment was quite telling. This is also true that initial generics of innovator drugs were given 15-20% less prices because the MoH was also unclear. Later, the prices of generic drugs kept going down and came down to even 10-15% of the innovator drug. Such low prices also caused concerns about efficacy in the beginning but settled later. Currently, the questions of efficacy and prices are settled. It is understood by doctors that generic versions may be similarly effective, but significantly less costly.

The prescriptions of generic products were further escalated due to the unprecedented, extraordinary services provided by the generic manufacturers. The patients became familiar with generic drugs through doctors’ prescriptions, and later developed their own confidence also. Some generic pharmaceuticals such as Dicloran are now household names, and public is greatly satisfied with their efficacy.

The last barrier to break was long term medications for chronic diseases such as heart disease, diabetes, metabolic disorders, and neuropsychiatry drugs. During late 1980 and 1990s, the MNCs made a great case against generic drugs in chronic care. Their major stances were two: the generic drugs did not ensure stated bioavailability, and the generic drugs would have batch to batch variations. Both factors would seriously impact the long-term control and outcome in patients. They might not have been entirely incorrect. However, the generic manufacturers improved quality control and the clinical experience did not endorse the fears raised by MNCs. Generic drugs are the mainstay of chronic diseases management.

Local Pharma has a great opportunity in this one fact. Pharma market is growing at a rapid pace in Pakistan. Among other factors, increase in doctors’ population and patient population are most significant. Local Pharma shall be the major beneficiary of these ongoing developments.

Presently, there are 117 medical colleges in Pakistan: 59 in public sector and 58 in private sector. The number of seats in various medical colleges ranges from 100 to 350. The number of doctors being produced every year is around 14,000 which is still less than what is required as per population. 70% of these are women, around 50% of whom do not work after marriage. This is a huge waste of public money and is affecting the health outcome further.

To be Continued……

Disclaimer. Most pictures in these blogs are taken from Google Images which does not show anyone’s copyright claim. However, if any such claim is presented, we shall remove the image with suitable regrets.

Exit mobile version